Functional erythropoietin autocrine loop in melanoma

American Journal of Pathology

Volumn 166, Issue 3, 2005, Pages 823-830

  Kumar, Suresh M ^a   Acs, Geza ^a   Fang, Dong ^b   Herlyn, Meenhard ^b   Elder, David E ^a   Xu, Xiaowei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; ERYTHROPOIESIS; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MELANOMA CELL; NEVUS; PARACRINE SIGNALING; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 14644401798     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62303-6     Document Type: Article

References (42)

1. Lappin T: The cellular biology of erythropoietin receptors. Oncologist 2003, 8(Suppl 1):15-18
2. Mulcahy L: The erythropoietin receptor. Semin Oncol 2001, 28:19-23
3. Erbayraktar S, Yilmaz O, Gokmen N, Brines M: Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2003, 2:465-470
4. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU: Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neural 2001, 60:386-392
5. Knabe W, Knerlich F, Washausen S, Kietzmann T, Siren AL, Brunnett G, Kuhn HJ, Ehrenreich H: Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat Embryol (Berl) 2004, 207:503-512
6. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001, 98:4044-4049
7. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93:2627-2636
8. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM: Expression of erythropoietin by the human placenta. FASEB J 1996, 10:760-768
9. Fairchild BD, Conrad KP: Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol Reprod 1999, 60:861-870
10. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD: Origin and fate of erythropoietin in human milk. Pediatr Res 2000, 48:660-667
11. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001, 61:3561-3565
12. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A: Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981
13. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990, 87:5978-5982
14. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y: Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002, 23:1797-1805
15. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003, 162:1789-1806
16. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y: Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001, 84:836-843
17. Acs G, Xu X, Chu C, Acs P, Verma A: Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004, 100:2376-2386
18. Chen C, Sytkowski AJ: Erythropoietin regulation of Raf-1 and MEK: evidence for a Ras-independent mechanism. Blood 2004, 104:73-80
19. Jacobs-Helber SM, Ryan JJ, Sawyer ST: JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood 2000, 96: 933-940
20. Nagata Y, Takahashi N, Davis RJ, Todokoro K: Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 1998, 92:1859-1869
21. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4:459-460
22. Powles T, Shamash J, Liu W: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004, 363:82
23. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ: Protein kinases in normal and transformed melanocytes. Melanoma Res 1994, 4:313-319
24. Xu X, Zhang PJ, Elder DE: Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch Pathol Lab Med 2003, 127:1083-1084
25. Bunn HF, Gu J, Huang LE, Park JW, Zhu H: Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 1998, 201:1197-1201
26. Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU: Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002, 99:3562-3565
27. Richards FM: Molecular pathology of von Hippel Lindau disease and the VHL tumour suppressor gene. Expert Rev Mol Med 2001, 2001:1-27
28. Wood L, Swanepoel C, du TA, Jacobs P: Clinically silent renal tumour producing erythropoietin. S Afr Med J 2003, 93:128-129
29. Rodeck U, Herlyn M: Growth factors in melanoma. Cancer Metastasis Rev 1991, 10:89-101
30. Payne AS, Cornelius LA: The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002, 118:915-922
31. Valyi-Nagy IT, Murphy GF, Mancianti ML, Whitaker D, Herlyn M: Phenotypes and interactions of human melanocytes and keratinocytes in an epidermal reconstruction model. Lab Invest 1990, 62: 314-324
32. Imokawa G, Yada Y, Morisaki N, Kimura M: Biological characterization of human fibroblast-derived mitogenic factors for human melanocytes. Biochem J 1998, 330:1235-1239
33. Halaban R: The regulation of normal melanocyte proliferation. Pigment Cell Res 2000, 13:4-14
34. Denko NC, Giaccia AJ: Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001, 61:795-798
35. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ: Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22:5907-5914
36. Park SK, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS: Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1 alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol 2003, 23:4959-4971
37. Gleadle JM, Ratcliffe PJ: Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997, 89:503-509
38. Ashley RA, Dubuque SH, Dvorak B, Woodward SS, Williams SK, Kling PJ: Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr Res 2002, 51:472-478
39. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M: Regulation of Notch1 and DII4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003, 23:14-25
40. Velazquez OC, Herlyn M: The vascular phenotype of melanoma metastasis. Clin Exp Metastasis 2003, 20:229-235
41. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003, 63:1684-1695
42. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003, 104:527-532